Keywords
alopecia areata,
psoriasis vulgaris,
Janus Kinase inhibitors,
How to Cite
Abstract
Monitoring and safety recommendations for primary care clinicians regarding Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitors in inflammatory skin disorders remain insufficiently defined [1, 2]. This review summarizes clinically
relevant and updated guidance on the monitoring, efficacy, and safety profiles of these agents. A systematic review of PubMed and U.S.
References
1. Beard A. JAK 1-3 Inhibitors and TYK-2 Inhibitors in Dermatology. J Dermatol Clin Res. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11610805/
2. Martin G. A Review of Tyrosine Kinase 2 Inhibitors. Dermatol Ther (Heidelb). 2023. https://link.springer.com/article/10.1007/s13555-022-00878-9
3. Zheng Y, Han Y, Chen J, et al. Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Indian J Dermatol Venereol
Leprol. 2024; 90: 590–598. https://ijdvl.com/comparative-efficacy-and-safety-of-jak-tyk2-inhibitors
4. Miot H A. JAK-STAT Pathway Inhibitors in Dermatology. J Dermatol Sci. 2023.
https://www.sciencedirect.com/science/article/pii/S0365059623001149
5. Ryguła I, Pikiewicz W, Kaminiów K. Novel Janus Kinase Inhibitors in the
Treatment of Dermatologic Conditions. Molecules. 2023; 28(24): 8064.
